Madison Investment Advisors’s AstraZeneca AZN Stock Holding History

Madison Investment Advisors’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	$3.33M	Buy	+25,395	New	+$3.56M	0.04%	202

Other funds holding AZN

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Sanders Capital West Palm Beach, Florida $99.8B AUM 47.9% 1-Year Est. Return

Madison Investment Advisors's AZN Position: Q4 2024 in Review

Madison Investment Advisors opened a new position in AstraZeneca (AZN) in Q4 2024: 25,395 shares worth $3.33M. The stake represents 0.04% of the portfolio and ranks #202 among its holdings.

1,219 funds tracked by Wall St. Rank hold AZN as of Q4 2024.

Madison Investment Advisors held 25,395 shares of AstraZeneca worth $3.33M as of Q4 2024.
AstraZeneca was a new Madison Investment Advisors position in Q4 2024.
AstraZeneca made up 0.04% of Madison Investment Advisors's portfolio in Q4 2024, its #202 holding.
1,219 funds tracked by Wall St. Rank held AstraZeneca as of Q4 2024.

Based on Madison Investment Advisors's 13F filing for Q4 2024, filed 10 Feb 2025.